Loading...
Market
Will Poseida's CAR-T therapy receive FDA approval by December 31, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA approval announcements or press releases from Roche or Poseida Therapeutics
Story
Roche to Acquire Poseida Therapeutics for $9 Per Share Plus $4 CVR in $1.5 Billion CAR-T Deal
Nov 26, 2024, 06:45 AM
Roche Holding AG has entered into a definitive agreement to acquire California-based Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in CAR-T cell therapies, for $9 per share in cash, totaling $1 billion upfront. Shareholders will also receive a non-tradeable contingent value right (CVR) of up to $4 per share, bringing the total potential value of the deal to $1.5 billion. This transaction represents a significant premium of approximately 200% over Poseida's recent share price. The acquisition includes Poseida's cell therapy candidates and related platform technologies, which focus on developing off-the-shelf CAR-T therapies for the treatment of autoimmune diseases, hematological malignancies, and solid tumors.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
